Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masatoshi Adachi

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Surgical Case Reports|February 12, 2016
Mid-facial deformity secondary to a traumatic haemorrhage in a maxillary cystMasatoshi Adachi, Yusuke Miyata, Yuki Ito
Odontology|August 3, 2013
A case of angioleiomyoma in the buccal spaceTomohiro Inaba, Masatoshi Adachi, Hisao Yagisita
Okajimas Folia Anatomica Japonica|June 22, 2010
Immunohistochemical and CBCT-based examination of differences between deformed and normal human condylar processesNoriko Kaneko, Rieko Asaumi, Masatoshi Adachi
Future Oncology (London, England)|January 13, 2022
Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenibTeruo Inamoto, Haruhito Azuma, Masatoshi Adachi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 24, 2016
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive CasesMototsugu Oya, Katsunori Tatsugami, Koki Kabu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 16, 2012
[Serum pancreatic enzyme elevation under treatment with sorafenib]Ichinosuke Hyodo, Masatoshi Adachi, Taiji Tsukamoto, et al.
Expert Review of Anticancer Therapy|May 23, 2020
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in JapanTeruo Inamoto, Haruhito Azuma, Katsunori Tatsugami, et al.
Cancers|June 13, 2025
Beneficial Outcomes of Immunoenhancing Nutritional Interventions in Perioperative Care for Oral Cancer: A Systematic Review and Meta-AnalysisShin-Ichiro Hiraoka, Takahiro Abe, Masahiro Watanabe, et al.
The Journal of Dermatology|February 24, 2011
Sorafenib-associated hand-foot syndrome in Japanese patientsMasafumi Iijima, Koichi Fukino, Masatoshi Adachi, et al.
Japanese Journal of Clinical Oncology|July 25, 2015
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillanceHideyuki Akaza, Mototsugu Oya, Masafumi Iijima, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Surgical Case Reports|February 12, 2016
Mid-facial deformity secondary to a traumatic haemorrhage in a maxillary cystMasatoshi Adachi, Yusuke Miyata, Yuki Ito
Odontology|August 3, 2013
A case of angioleiomyoma in the buccal spaceTomohiro Inaba, Masatoshi Adachi, Hisao Yagisita
Okajimas Folia Anatomica Japonica|June 22, 2010
Immunohistochemical and CBCT-based examination of differences between deformed and normal human condylar processesNoriko Kaneko, Rieko Asaumi, Masatoshi Adachi
Future Oncology (London, England)|January 13, 2022
Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenibTeruo Inamoto, Haruhito Azuma, Masatoshi Adachi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 24, 2016
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive CasesMototsugu Oya, Katsunori Tatsugami, Koki Kabu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 16, 2012
[Serum pancreatic enzyme elevation under treatment with sorafenib]Ichinosuke Hyodo, Masatoshi Adachi, Taiji Tsukamoto, et al.
Expert Review of Anticancer Therapy|May 23, 2020
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in JapanTeruo Inamoto, Haruhito Azuma, Katsunori Tatsugami, et al.
Cancers|June 13, 2025
Beneficial Outcomes of Immunoenhancing Nutritional Interventions in Perioperative Care for Oral Cancer: A Systematic Review and Meta-AnalysisShin-Ichiro Hiraoka, Takahiro Abe, Masahiro Watanabe, et al.
The Journal of Dermatology|February 24, 2011
Sorafenib-associated hand-foot syndrome in Japanese patientsMasafumi Iijima, Koichi Fukino, Masatoshi Adachi, et al.
Japanese Journal of Clinical Oncology|July 25, 2015
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillanceHideyuki Akaza, Mototsugu Oya, Masafumi Iijima, et al.
Pageof 2